Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gustavo Mondragon

Cardiovascular Disease Chula Vista, CA Medical Doctor

NPI 1619080041 CMS profile 300217

480 Fourth Ave Ste 500, Chula Vista, CA 91910

Open in the dashboard

General payments

$6,679

365 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gustavo Mondragon of Chula Vista, CA is reported in the CMS Open Payments database as having received $6,679 across 365 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $682 30
2024 General $1,039 57
2023 General $975 56
2022 General $1,219 71
2021 General $1,134 66
2020 General $547 29
2019 General $1,082 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gustavo Mondragon
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Gustavo Mondragon were reported at $682. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Gustavo Mondragon Cardiovascular Disease median Middle half National median
2019 $1,082 $450 $127–$1,392 $163
2020 $547 $242 $77–$751 $114
2021 $1,134 $335 $101–$1,037 $132
2022 $1,219 $395 $121–$1,211 $149
2023 $975 $443 $136–$1,283 $160
2024 $1,039 $450 $136–$1,323 $164
2025 $682 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,649 103 payments
  2. Esperion Therapeutics, Inc. $851 51 payments
  3. Actelion Pharmaceuticals US, Inc. $668 53 payments
  4. Novo Nordisk Inc $600 26 payments
  5. Amgen Inc. $369 19 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $260 10 payments
  7. Xeris Pharmaceuticals, Inc. $201 9 payments
  8. Dexcom, Inc. $166 7 payments
  9. Lilly USA, LLC $158 7 payments
  10. Ironwood Pharmaceuticals, Inc $132 6 payments
  11. Other $1,626 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,666 364 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. NEXLETOL $851 51 payments
  2. ENTRESTO $846 50 payments
  3. UPTRAVI $657 52 payments
  4. OPSUMIT $650 52 payments
  5. LEQVIO Cardiology/Vascular Diseases $434 28 payments
  6. Repatha $278 14 payments
  7. Ozempic $267 14 payments
  8. LEQVIO Cardiovascular $261 19 payments
  9. JARDIANCE $260 10 payments
  10. Saxenda $257 8 payments
  11. Other $2,923 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

11,328

Median for Cardiology: 2,533

Drug cost

$1,825,811

Median for Cardiology: $485,213

Branded share of claims

21.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 23 $277,858
Eliquis Apixaban Brand 238 $267,175
Entresto Sacubitril/Valsartan Brand 147 $176,192
Jardiance Empagliflozin Brand 174 $174,473
Ozempic Semaglutide Brand 141 $165,712
Januvia Sitagliptin Phosphate Brand 119 $119,954
Trulicity Dulaglutide Brand 87 $100,422
Linzess Linaclotide Brand 38 $39,068
Farxiga Dapagliflozin Propanediol Brand 43 $38,897
Leqvio Inclisiran Sodium Brand 12 $36,974

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$81,699

Medicare's payments for the services billed

Medicare patients

148

Average age 80

Services billed

1,113

99 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 52%
Heart failure 45%
Chronic kidney disease 40%
Atrial fibrillation 35%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NEXLETOL
  • Esperion Therapeutics, Inc. $138
$138 15 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $114
$114 12 —
Linzess
  • Ironwood Pharmaceuticals, Inc $95
$95 38 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $69
$69 23 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

365 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record